Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study.
Budde K, Lehner F, Sommerer C, Reinke P, Arns W, Eisenberger U, Wüthrich RP, Mühlfeld A, Heller K, Porstner M, Veit J, Paulus EM, Witzke O; ZEUS Study Investigators. Budde K, et al. Among authors: veit j. Am J Transplant. 2015 Jan;15(1):119-28. doi: 10.1111/ajt.12952. Epub 2014 Dec 17. Am J Transplant. 2015. PMID: 25521535 Free article. Clinical Trial.
Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy.
Sommerer C, Duerr M, Witzke O, Lehner F, Arns W, Kliem V, Ackermann D, Guba M, Jacobi J, Hauser IA, Stahl R, Reinke P, Rath T, Veit J, Mehrabi A, Porstner M, Budde K; HERAKLES Study Group. Sommerer C, et al. Among authors: veit j. Am J Transplant. 2018 Dec;18(12):2965-2976. doi: 10.1111/ajt.14897. Epub 2018 Jun 3. Am J Transplant. 2018. PMID: 29722128 Free article. Clinical Trial.
Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate.
Poddubnyy D, Hammel L, Heyne M, Veit J, Jentzsch C, Baraliakos X. Poddubnyy D, et al. Among authors: veit j. BMJ Open. 2020 Sep 30;10(9):e039059. doi: 10.1136/bmjopen-2020-039059. BMJ Open. 2020. PMID: 32998926 Free PMC article.
Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study.
Kiltz U, Sfikakis PP, Gaffney K, Sator PG, von Kiedrowski R, Bounas A, Gullick N, Conrad C, Rigopoulos D, Lespessailles E, Romanelli M, Ghislain PD, Brandt-Jürgens J, Rashkov R, Aassi M, Orsenigo R, Perella C, Pournara E, Gathmann S, Jagiello P, Veit J, Augustin M. Kiltz U, et al. Among authors: veit j. Adv Ther. 2020 Jun;37(6):2865-2883. doi: 10.1007/s12325-020-01352-8. Epub 2020 May 6. Adv Ther. 2020. PMID: 32378070 Free PMC article.
Multiplex PCR for bacterial, viral and protozoal pathogens in persistent diarrhoea or persistent abdominal pain in Côte d'Ivoire, Mali and Nepal.
Jasuja JK, Bub F, Veit J, Fofana HKM, Sacko M, Saye R, Chatigre JK, N'Goran EK, Yao JA, Khanal B, Koirala K, Bhattarai NR, Rijal S, von Müller L, Bottieau E, Boelaert M, Chappuis F, Polman K, Utzinger J, Becker SL. Jasuja JK, et al. Among authors: veit j. Sci Rep. 2024 May 13;14(1):10926. doi: 10.1038/s41598-024-60491-y. Sci Rep. 2024. PMID: 38740833 Free PMC article.
OpenMS 3 enables reproducible analysis of large-scale mass spectrometry data.
Pfeuffer J, Bielow C, Wein S, Jeong K, Netz E, Walter A, Alka O, Nilse L, Colaianni PD, McCloskey D, Kim J, Rosenberger G, Bichmann L, Walzer M, Veit J, Boudaud B, Bernt M, Patikas N, Pilz M, Startek MP, Kutuzova S, Heumos L, Charkow J, Sing JC, Feroz A, Siraj A, Weisser H, Dijkstra TMH, Perez-Riverol Y, Röst H, Kohlbacher O, Sachsenberg T. Pfeuffer J, et al. Among authors: veit j. Nat Methods. 2024 Mar;21(3):365-367. doi: 10.1038/s41592-024-02197-7. Nat Methods. 2024. PMID: 38366242 No abstract available.
133 results